Coccidioidomycosis
15
1
2
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
20.0%
3 terminated out of 15 trials
72.7%
-13.8% vs benchmark
27%
4 trials in Phase 3/4
63%
5 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment
To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum Females
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.
Safety and Pharmacokinetics of VT-1598
An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)
Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis
SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
A Multi-center Study of Spherule-Derived Coccidioidin
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common